Skip to main content
Fig. 3 | Arthritis Research & Therapy

Fig. 3

From: Tofacitinib facilitates the expansion of myeloid-derived suppressor cells and ameliorates interstitial lung disease in SKG mice

Fig. 3

Lung MDSCs are increased in the lungs of tofacitinib-treated mice and suppress T cell proliferation and Th17 cell differentiation ex vivo. a Representative flow cytometry plots of MDSCs from the lungs of control mice and tofacitinib-treated mice. b Comparison of the lung-infiltrating MDSCs in control mice (n = 5) versus tofacitinib-treated mice (n = 5). c CFSE-labeled CD4+ T cells were cultured for 3 days with CD3 and CD28 stimulation, with or without the indicated proportion of lung MDSCs obtained from Zym-injected SKG mice. d Representative flow cytometry plots of the Th17 cell differentiation assay. In addition to the proliferation conditions, the following cytokines and antibodies were added: 10 ng/ml IL-6, 0.5 ng/ml TGF-β, 2.5 μg/ml anti-IFNγ, and 2.5 μg/ml anti-IL-4. e Proportion of Th17 cells obtained after CD4+ T cells were cultured with or without lung MDSCs (MDSCs, n = 5; control, n = 5). Data are shown as the mean ± SEM. *P < 0.05, ***P < 0.001, Mann-Whitney U tests

Back to article page